Wells Fargo analyst Brandon Couillard downgraded Myriad Genetics (MYGN) to Equal Weight from Overweight with a price target of $6, down from $22.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Reports Mixed Q1 2025 Results
- Myriad Genetics Faces Revenue Declines and Strategic Challenges: Hold Rating Maintained
- Myriad Genetics cuts FY25 adjusted EPS view to (2c)-2c from 7c-11c
- Myriad Genetics reports Q1 adjusted EPS (3c), consensus (5c)
- Myriad Genetics announces survey results on depression, anxiety